Discontinuation rate during induction and maintenance in patients who started treatment
| . | MPT-T . | MPR-R . | ||
|---|---|---|---|---|
| ≤75 years (N = 209) . | ≥76 years (N = 104) . | ≤75 years (N = 209) . | ≥76 years (N = 109) . | |
| Induction | ||||
| Patients completing 6 induction cycles, N (%) | 162 (78) | 71 (68) | 160 (77) | 80 (73) |
| Patients reaching maintenance, N (%) | 121 (58) | 41 (39) | 124 (59) | 65 (60) |
| Discontinuation due to toxicity, N (%)* | 43 (21) | 33 (32) | 36 (17) | 29 (27) |
| Maintenance | ||||
| Number of patients starting maintenance | 121 | 41 | 124 | 65 |
| Number of patients discontinuing maintenance (%) | 109 (90) | 37 (90) | 87 (70) | 44 (68) |
| Discontinued due to toxicity, N (%)† | 73 (67) | 25 (68) | 20 (16) | 13 (20) |
| Median duration of maintenance therapy in months‡ | 5 | 5 | 17 | 15 |
| . | MPT-T . | MPR-R . | ||
|---|---|---|---|---|
| ≤75 years (N = 209) . | ≥76 years (N = 104) . | ≤75 years (N = 209) . | ≥76 years (N = 109) . | |
| Induction | ||||
| Patients completing 6 induction cycles, N (%) | 162 (78) | 71 (68) | 160 (77) | 80 (73) |
| Patients reaching maintenance, N (%) | 121 (58) | 41 (39) | 124 (59) | 65 (60) |
| Discontinuation due to toxicity, N (%)* | 43 (21) | 33 (32) | 36 (17) | 29 (27) |
| Maintenance | ||||
| Number of patients starting maintenance | 121 | 41 | 124 | 65 |
| Number of patients discontinuing maintenance (%) | 109 (90) | 37 (90) | 87 (70) | 44 (68) |
| Discontinued due to toxicity, N (%)† | 73 (67) | 25 (68) | 20 (16) | 13 (20) |
| Median duration of maintenance therapy in months‡ | 5 | 5 | 17 | 15 |
Significantly higher in all patients ≥76 vs ≤75 years (P = .005) and in the subgroup of patients in the MPT-T arm (P = .036) but not for MPR-R (P = .057).
Significantly higher in MPT-T vs MPR-R in all patients together, as well as in the subgroups of patients ≤75 and ≥76 years (P < .001).
Significantly shorter in MPT-T vs MPR-R in all patients together, as well as in the subgroups of patients ≤75 (P < .001) and ≥76 years (P = .001).